Anti-Jo-1 autoantibodies: biomarkers of severity and evolution of the disease in antisynthetase syndrome [PDF]
Arthritis Research & Therapy, 2023 Background Anti-Jo-1 autoantibodies represent essential markers in the diagnosis of antisynthetase syndrome (ASS). In this retrospective study, we aimed to investigate whether their concentrations and fluctuations could both respectively reflect the ...
Robin Arcani +12 more
doaj +2 more sources
Differences in the Clinical Characteristics and 1-Year Mortality Rates of Patients with Dermatomyositis with anti-Jo-1 and anti-MDA5 Antibodies [PDF]
Journal of Immunology Research, 2023 Objective. Patients with anti-Jo-1 antibodies (Abs) and anti–melanoma differentiation-associated protein 5 (MDA5) Abs are at a higher risk of interstitial lung disease (ILD) and have a mortality rate higher than that of patients with anti-Jo-1 Abs.
Chao-Han Liu +5 more
doaj +2 more sources
COVID-19 vaccination-associated anti-Jo-1 syndrome [PDF]
Rheumatology, 2021 Post-vaccination inflammatory myositis is a rare but known entity in the literature. We encountered a 46-year-old female patient, who presented with complains of fever, arthralgia, and weakness 1 week after taking the second dose of COVID-19 (Oxford ...
Kushagra Gupta +2 more
doaj +2 more sources
A Case of Anti-Jo-1 Myositis with Unique Biopsy Findings [PDF]
Case Reports in Rheumatology, 2022 Antisynthetase syndrome (ASS) or anti-Jo-1 antibody syndrome has a classic clinical presentation including arthritis, myositis, interstitial lung disease, mechanic hands, and/or Raynaud’s phenomenon.
Beenish Zulfiqar +3 more
doaj +2 more sources
Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis [PDF]
Arthritis Research & Therapy, 2018 Background B-cell activating factor of the tumour necrosis factor family (BAFF) plays a role in autoantibody production and is elevated in dermatomyositis (DM) and anti-Jo-1-positive polymyositis (PM).
Olga Kryštůfková +7 more
doaj +2 more sources
What does it mean if a patient is positive for anti-Jo-1 in routine hospital practice? A retrospective nested case-control study [version 1; referees: 2 approved] [PDF]
F1000Research, 2018 Background: It is widely believed that patients bearing auto-antibodies to histidyl tRNA synthetase (anti-Jo-1) very likely have a connective tissue disease including myositis and interstitial lung disease.
Paresh Jobanputra +4 more
doaj +2 more sources
Clinical and prognostic associations of anti-Jo-1 antibody levels in patients with antisynthetase syndrome [PDF]
Respiratory ResearchObjective To investigate the association of serum anti-Jo-1 antibody levels with the disease activity and prognosis in anti-Jo-1-positive patients with antisynthetase syndrome (ASS).
Hongxia Yang +8 more
doaj +2 more sources
CD73low B-cell phenotypes and distinct cytokine profiles in patients with active anti-Jo-1 antibody positive idiopathic inflammatory myopathies [PDF]
RMD OpenObjectives We performed multiparameter phenotyping of peripheral B cells in anti-Jo-1 antibody positive idiopathic inflammatory myopathies (IIM) to delineate disease-associated immunological profiles and the influence of B cells on disease activity ...
Ingrid E Lundberg +6 more
doaj +2 more sources
Successful Treatment of Anti-Jo-1 Positive Inflammatory Myopathy With Tofacitinib [PDF]
Case Reports in RheumatologyIdiopathic inflammatory myopathies are, in some cases, refractory to all guideline-based treatments, posing a very difficult challenge in clinical practice.
Janis Timsans +5 more
doaj +2 more sources
Dose-Escalated Upadacitinib for Refractory Myositis in Anti-Jo-1-Positive Antisynthetase Syndrome: A Case Report [PDF]
Case Reports in RheumatologyAnti-Jo-1-positive antisynthetase syndrome (ASS) can follow a relapsing course during glucocorticoid tapering, and evidence for refractory myositis remains limited.
Yuji Kukida, Hironori Inoue
doaj +2 more sources